Oncolytics Biotech® to Participate in a Panel Discussion at the Canaccord Genuity Horizons in Oncology Virtual Conference
Oncolytics Biotech (NASDAQ: ONCY) announced that CEO Dr. Matt Coffey will participate in a panel discussion titled "Off-the-Shelf CAR T - solid tumors, myeloma, lymphoma" at the Canaccord Genuity Horizons in Oncology Virtual Conference.
Date: April 15, 2021, Time: 8:15 am ET.
Oncolytics is advancing its immuno-oncolytic virus, pelareorep, targeting various cancers. They are preparing for a Phase 3 registration study in metastatic breast cancer, exploring synergies with approved immuno-oncology therapies.
- None.
- None.
SAN DIEGO and CALGARY, Alberta, April 8, 2021 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that Dr. Matt Coffey, the Company's President and Chief Executive Officer, will be participating in a panel discussion at the Canaccord Genuity Horizons in Oncology Virtual Conference. Details on the panel discussion are provided below.
Title: Off-the-Shelf CAR T - solid tumors, myeloma, lymphoma
Date: Thursday, April 15, 2021
Time: 8:15 am ET
Company management will also be participating in one-on-one investor meetings at the conference. To schedule a meeting, please contact your Canaccord representative or email tim@lifesciadvisors.com.
About Oncolytics Biotech Inc.
Oncolytics is a biotechnology company developing pelareorep, an intravenously delivered immuno-oncolytic virus. The compound induces selective tumor lysis and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and adaptive immune responses to treat a variety of cancers.
Pelareorep has demonstrated synergies with immune checkpoint inhibitors and may also be synergistic with other approved immuno-oncology agents. Oncolytics is currently conducting and planning additional studies of pelareorep in combination with checkpoint inhibitors and targeted therapies in solid and hematological malignancies, as it prepares for a phase 3 registration study in metastatic breast cancer. For further information, please visit: www.oncolyticsbiotech.com.
This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended and forward-looking information under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred to herein as "forward-looking statements"). Forward-looking statements contained in this press release include statements regarding Oncolytics' belief as to the potential and benefits of pelareorep as a cancer therapeutic; Oncolytics' expectations as to the purpose, design, outcomes and benefits of its current or pending clinical trials involving pelareorep; and other statements related to anticipated developments in Oncolytics' business and technologies. In any forward-looking statement in which Oncolytics expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will be achieved. Such forward-looking statements involve known and unknown risks and uncertainties, which could cause Oncolytics' actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of pelareorep as a cancer treatment, the success and timely completion of clinical studies and trials, Oncolytics' ability to successfully commercialize pelareorep, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. In particular, we may be impacted by business interruptions resulting from COVID-19 coronavirus, including operating, manufacturing supply chain, clinical trial and project development delays and disruptions, labour shortages, travel and shipping disruption, and shutdowns (including as a result of government regulation and prevention measures). It is unknown whether and how Oncolytics may be affected if the COVID-19 pandemic persists for an extended period of time. We may incur expenses or delays relating to such events outside of our control, which could have a material adverse impact on our business, operating results and financial condition. Investors should consult Oncolytics' quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake any obligation to update these forward-looking statements, except as required by applicable laws.
Contact:
Company Contact
Kirk Look
Chief Financial Officer
+1-403-670-7658
KLook@oncolytics.ca
Investor Relations for Oncolytics
Timothy McCarthy
LifeSci Advisors
+1-917-679-9282
tim@lifesciadvisors.com
View original content:http://www.prnewswire.com/news-releases/oncolytics-biotech-to-participate-in-a-panel-discussion-at-the-canaccord-genuity-horizons-in-oncology-virtual-conference-301264756.html
SOURCE Oncolytics Biotech® Inc.
FAQ
What is the date and time of Oncolytics' panel discussion at the Canaccord Genuity Horizons in Oncology Virtual Conference?
Who is participating in the Canaccord Genuity Oncology Conference for Oncolytics?
What topics will be discussed in Oncolytics' panel at the conference?
What is pelareorep and its significance for Oncolytics Biotech?
Is Oncolytics planning any further studies for pelareorep?
